Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.
Neurocrine price target raised to $176 from $162 at UBS
UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...
PepGen Inc. (PEPG) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) today and set a price target of $17.00.